Analysis of Cervical Cancer Management at Primary and Tertiary Healthcare Facilities in Rivers State

K.C. Oweh; K.G. McFubara; A. Bademosi

doi:10.56201/ijmepr.v10.no1.2026.pg1.13

📄 Download Paper

Analysis of Cervical Cancer Management at Primary and Tertiary Healthcare Facilities in Rivers State

K.C. Oweh, K.G. McFubara and, A. Bademosi

Abstract

Cervical cancer remains a significant public health concern, and differences in management between primary and tertiary healthcare facilities may influence early detection and treatment outcomes. This study aimed to compare cervical cancer prevalence and management between a tertiary and primary healthcare facility (PHC Ozuoba) in Rivers State. A retrospective cross-sectional design reviewed 6,020 women screened from 2021 to 2023. Data on sociodemographics, risk factors, management, and follow-up were extracted from hospital records. Descriptive statistics and chi-square tests were used to assess differences between facilities. Overall prevalence was 1.0% (95% CI: 0.8–1.3%), with RSUTH at 1.1% (95% CI: 0.8–1.5%) and PHC Ozuoba at 0.9% (95% CI: 0.6–1.3%). Most positive cases were aged 30– 39 years (48.4%), with similar age distributions across facilities. Risk factors, including multiple sexual partners, oral contraceptive use, and high parity, were comparable. Screening methods differed significantly: VIA was more frequent at RSUTH (75.7%) than PHC (24.3%, p < 0.001), while PAP smear was performed only at RSUTH (100%, p = 0.011). Thermal ablation was the primary treatment at both facilities, but RSUTH managed a higher proportion of cases via this method (48.1% vs 51.9%, p = 0.015). Post-treatment follow-up showed limited cured cases, with no significant difference between RSUTH and PHC (2.9% vs 0%, p = 0.548). Cervical cancer prevalence was similar across facilities, but tertiary care offered broader screening and treatment capacity. Strengthening management resources and follow-up protocols at primary healthcare centres is recommended to improve patient outcomes.

Keywords

Cervical cancerPrimary healthcareTertiary healthcareComparative managementScreening methods

References

Boon, S. S., Luk, H. Y., Xiao, C., Chen, Z., & Chan, P. K. S. (2022). Review of the standard and advanced screening, staging systems and treatment modalities for cervical cancer. Cancers, 14(12), 2913. Chou, B., Venkatesulu, B. P., Coleman, R. L., Harkenrider, M., & Small Jr, W. (2022). Management of stage I and II cervical cancer: a review. International Journal of Gynecological Cancer, 32(3), 216-224. Ehwarieme, E. V., et al. (2025). [Assuming this is an in-prep or forthcoming study; confirm full reference if available] Gatta, G., Capocaccia, R., Botta, L., Mallone, S., De Angelis, R., Ardanaz, E. (2017). Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study. The Lancet Oncology, 18(8), 1022–1039. Guimarães, Y. M., Godoy, L. R., Longatto-Filho, A., & Reis, R. D. (2022). Management of early-stage cervical cancer: a literature review. Cancers, 14(3), 575. Huang, J., Deng, Y., Boakye, D., Tin, M. S., Lok, V., Zhang, L., ... & NCD Global Health Research Group. (2022). Global distribution, risk factors, and recent trends for cervical cancer: a worldwide country-level analysis. Gynecologic Oncology, 164(1), 85–92. Justina, O. (2021). Cervical cancer trend and associated risk factors at a North-Western Nigerian Hospital. EC Gynaecol, 10, 01–10. Martel, C., Plummer, M., Vignat, J., & Franceschi, S. (2017). Worldwide burden of cancer attributable to HPV by site, country and HPV type. International Journal of Cancer, 141(4), 664–670. Qin, F., Pang, H., Yu, T., Luo, Y., & Dong, Y. (2022). Treatment strategies and prognostic factors of 2018 FIGO stage IIIC cervical cancer: a review. Technology in Cancer Research & Treatment, 21, 15330338221086403. Ramachandran, D., Dörk, T. (2021). Genomic risk factors for cervical cancer. Cancers, 13(20), 5137. Shahnaz, S., Hira, H. M., Begum, K. N., Akhter, R., Sharmin, S. (2021). “Screen and Treat” approach among VIA positive women during cervical cancer screening program: experience at low resource setting. Mymensingh Med J MMJ, 30(4), 1100–1106. Simms, K. T., Steinberg, J., Caruana, M., Smith, M. A., Lew, J. B., & Soerjomataram, I. (2019). Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries. The Lancet Oncology, 20(3), 394–407. Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics, GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249. Tewari, K. S. (2025). Cervical Cancer. New England Journal of Medicine, 392(1), 56–71. Wassie, M., & Fentie, B. (2021). Prevalence of late-stage presentation and associated factors of cervical cancer patients in Tikur Anbesa Specialized Hospital, Ethiopia: institutional based cross-sectional study. Infectious Agents and Cancer, 16(1), 30. World Health Organization. (2020). Global strategy to accelerate the elimination of cervical cancer as a public health problem. Geneva: WHO. Zhang, S., Xu, H., Zhang, L., & Qiao, Y. (2020). Cervical cancer: Epidemiology, risk factors and screening. Chinese Journal of Cancer Research, 32(6), 720.

Analysis of Cervical Cancer Management at Primary and Tertiary Healthcare Facilities in Rivers State

Abstract

Keywords

References

More Articles from INTERNATIONAL JOURNAL OF MEDICAL EVALUATION AND PHYSICAL REPORT